This site is intended for Healthcare professionals only.

Glenmark Pharma gets Marketing Authorisation for generic version of COPD drug in Germany


Glenmark Pharma gets Marketing Authorisation for generic version of COPD drug in Germany

It is used to treat asthma and chronic obstructive pulmonary disease (COPD).

New Delhi: Glenmark Pharma’s subsidiary has secured marketing authorisation in Germany for the generic version of GlaxoSmithKline’s Seretide Accuhaler, used to treat asthma.

“Fluticasone/Salmeterol DPI is a combination product for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Glenmark will sell the product in Germany under the name ‘Salflutin’,” the company said in a BSE filing.

Glenmark Pharmaceuticals Executive Vice President and Business Head of Europe and Latin America, Achin Gupta, said that upon launch, generic Fluticasone/Salmeterol DPI will be Glenmark’s first inhalation product available in Germany.

“There is huge potential for the product in Germany and we are optimistic that it will help enhance the growth of the European business,” he added.

The company has already launched this product in Denmark, Sweden and Norway, it added.

Quoting IQVIA data, Glenmark Pharma said Fluticasone/Salmeterol dry powder inhaler (DPI) had sales of $844 million in Europe in the 12-month period ending March 2018.

 



Source: PTI
0 comment(s) on Glenmark Pharma gets Marketing Authorisation for generic version of COPD drug in Germany

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted